Cited by 786Genetics, Aging, and Longevity in Model OrganismsT-cell and B-cell ImmunologyPI3K/AKT/mTOR signaling in cancer

mTOR inhibition improves immune function in the elderly

Mannick, Joan B., Del Giudice, Giuseppe, Lattanzi, Maria, Valiante, Nicholas M., Praestgaard, Jens, Huang, Baisong, Lonetto, Michael A., Maecker, Holden T. +4 more·2014·Science Translational Medicine

Abstract

mTOR inhibition by RAD001 improves immune responses in elderly volunteers receiving an influenza vaccination.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.3009892

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several rapalogs, including everolimus, have been tested in humans, with mTOR inhibition leading to improved vaccination responses in the elderly, possibly through targeting immunosenescence.

    “Several rapalogs, including everolimus, have also been tested in humans, with mTOR inhibition leading to improved vaccination responses in the elderly, possibly through targeting immunosenescence (Mannick et al. 2014).”

    From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Mannick et al. 2014

  • Administration of the mTOR inhibitor RAD001 improved the response to influenza vaccine in the elderly by around 20%.

    “Administration of a rapalog, mTOR inhibitor RAD001, showed improved response to the influenza vaccine in the elderly by around 20%171.”

    From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [171]

  • Inhibition of mTOR increases the general immune response to vaccination in the elderly.

    “Inhibition of mTOR has been shown to increase the general immune response to vaccination in the elderly [145], and might be relevant in designing new therapeutic strategies.”
  • Combined BEZ235 and everolimus treatment for 6 weeks resulted in better infection control in older adults for a year after treatment ended.

    “follow-up study, combined BEZ235 (a dual ATP-competitive PI3K and mTOR inhibitor) and everolimus treatment for 6 weeks resulted in better infection control in older adults for a year after treatment had ended (207).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mannick, J. B., Del Giudice, G., Lattanzi, M., Valiante, N. M., Praestgaard, J., Huang, B., Lonetto, M. A., Maecker, H. T., Kovarik, J., Carson, S., Glass, D. J., & Klickstein, L. B.
Affiliations
  • Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA.
  • Novartis Vaccines and Diagnostics, 53100 Siena, Italy.
  • Novartis Vaccines and Diagnostics, Cambridge, MA 02139, USA.
  • Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
  • Novartis (Switzerland) (CH)
  • Stanford Medicine (US)
  • Southern Clinical Trials, Christchurch 8024, New Zealand.
Corresponding author
Mannick, Joan B.
Venue
Science Translational Medicine
Published
2014-12-24
Volume
6
Issue
268
Pages
268ra179-268ra179
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2149010238
Cited by
786
References
23
Citations by year
2026: 77 · 2025: 79 · 2024: 63 · 2023: 74 · 2022: 66 · 2021: 80 · 2020: 76 · 2019: 57 · 2018: 60 · 2017: 58 · 2016: 50 · 2015: 45 · 2013: 1
FWCI
17.44
Type
journal article
Language
en
Open access
closed
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
mTOR inhibition, everolimus, immunosenescence, aging, older adults, PD-1, T cells, immune function, rapamycin analogs
MeSH terms
Everolimus, Aged, Antibodies, Viral, Humans, Immunity, Influenza Vaccines, Placebos, Seasons, Vaccination, Cohort Studies, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Sirolimus, Protein Kinase Inhibitors, TOR Serine-Threonine Kinases, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review